Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199

References

• Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997–2002. Cancer Causes Control. 2008;19(4):379–390.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–474.
   PubMed Web of Science ®Google Scholar
• Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136–1152.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354–365.
   PubMed Web of Science ®Google Scholar
• Kadia T, Kantarjian H, Garcia-Manero G, et al. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol. 2015;170(4):590–593.
   PubMed Web of Science ®Google Scholar
• Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26(9):1324–1337.
   PubMed Web of Science ®Google Scholar
• Cang S, Iragavarapu C, Savooji J, et al. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol. 2015;8:129.
   PubMed Web of Science ®Google Scholar
• Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4(3):362–375.
   PubMed Web of Science ®Google Scholar
• Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532–1542.
   PubMed Web of Science ®Google Scholar
• Levis M, Small D. FLT3: iTDoes matter in leukemia. Leukemia. 2003;17(9):1738–1752.
   PubMed Web of Science ®Google Scholar
• Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100(1):59–66.
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100(13):4372–4380.
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752–1759.
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Towatari M, Yokota S, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia. 1998;12(9):1333–1337.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368(22):2059–2074.
   PubMed Web of Science ®Google Scholar
• Carow CE, Kim E, Hawkins AL, et al. Localization of the human stem cell tyrosine kinase-1 gene (FLT3) to 13q12–>q13. Cytogenet Cell Genet. 1995;70(3–4):255–257.
   PubMedGoogle Scholar
• Van Der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol. 1994;10:251–337.
   PubMedGoogle Scholar
• Schnittger S, Bacher U, Haferlach C, et al. Diversity of the juxtamembrane and TKD1 mutations (exons 13–15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data. Genes Chromosomes Cancer. 2012;51(10):910–924.
   PubMed Web of Science ®Google Scholar
• Kayser S, Schlenk RF, Londono MC, et al. Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood. 2009;114(12):2386–2392.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97(8):2434–2439.
   PubMed Web of Science ®Google Scholar
• Abu-Duhier FM, Goodeve AC, Wilson GA, et al. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol. 2001;113(4):983–988.
   PubMed Web of Science ®Google Scholar
• Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326–4335.
   PubMed Web of Science ®Google Scholar
• Moreno I, Martin G, Bolufer P, et al. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica. 2003;88(1):19–24.
   PubMed Web of Science ®Google Scholar
• Levis M, Tse KF, Smith BD, et al. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood. 2001;98(3):885–887.
   PubMed Web of Science ®Google Scholar
• Tse KF, Novelli E, Civin CI, et al. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia. 2001;15(7):1001–1010.
   PubMed Web of Science ®Google Scholar
• Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood. 2005;105(3):986–993.
   PubMed Web of Science ®Google Scholar
• Fiedler W, Kayser S, Kebenko M, et al. A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. Br J Haematol. 2015;169(5):694–700.
   PubMed Web of Science ®Google Scholar
• Metzelder SK, Schroeder T, Finck A, et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia. 2012;26(11):2353–2359.
   PubMed Web of Science ®Google Scholar
• Pratz KW, Cho E, Levis MJ, et al. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia. 2010;24(8):1437–1444.
   PubMed Web of Science ®Google Scholar
• Zhang W, Konopleva M, Shi YX, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008;100(3):184–198.
   PubMed Web of Science ®Google Scholar
• Borthakur G, Kantarjian H, Ravandi F, et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica. 2011;96(1):62–68.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clinical Oncology. 2010;28(11):1856–1862.
   PubMed Web of Science ®Google Scholar
• Al-Kali A, Cortes J, Faderl S, et al. Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2011;11(4):361–366.
   PubMed Web of Science ®Google Scholar
• Rollig C, Serve H, Huttmann A, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16(16):1691–1699.
   PubMed Web of Science ®Google Scholar
• Ding W, Knox TR, Tschumper RC, et al. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood. 2010;116(16):2984–2993.
   PubMed Web of Science ®Google Scholar
• Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95(8):2637–2644.
   PubMed Web of Science ®Google Scholar
• Serve H, Krug U, Wagner R, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clinical Oncology. 2013;31(25):3110–3118.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Alattar ML, Grunwald MR, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013;121(23):4655–4662.
   PubMed Web of Science ®Google Scholar
• Ohanian M, Garcia-Manero G, Jabbour EJ, et al. Combination of Sorafenib and 5-Azacytidine in older patients with untreated Acute Myeloid Leukemia with FLT3-ITD mutation. Blood (ASH Annual Meeting Abstracts). 2016;128:1611.
   Web of Science ®Google Scholar
• Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105(1):54–60.
   PubMed Web of Science ®Google Scholar
• Fischer T, Stone RM, Deangelo DJ, et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clinical Oncology. 2010;28(28):4339–4345.
   PubMed Web of Science ®Google Scholar
• Stone RM, Fischer T, Paquette R, et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia. Leukemia. 2012;26(9):2061–2068.
   PubMed Web of Science ®Google Scholar
• Stone RM, Sanford BL, Geyer S, et al. The multi-kinase inhibitor Midostaurin (M) prolongs survival compared with Placebo (P) in combination with Daunorubicin(D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and as maintenance (maint) therapy in newly diagnosed Acute Myeloid Leukemia (AML) Patients (pts) age 18–60 with FLT3 Mutations (muts): an International Prospective Randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]). Blood (ASH Annual Meeting Abstracts). 2015;126:6.
   PubMed Web of Science ®Google Scholar
• Cooper BW, Kindwall-Keller TL, Craig MD, et al. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients. Clin Lymphoma Myeloma Leuk. 2015;15(7):428–32e2.
   PubMed Web of Science ®Google Scholar
• Strati P, Kantarjian H, Ravandi F, et al. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015;90(4):276–281.
   PubMed Web of Science ®Google Scholar
• Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004;103(10):3669–3676.
   PubMed Web of Science ®Google Scholar
• Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 2006;108(10):3262–3270.
   PubMed Web of Science ®Google Scholar
• Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011;117(12):3294–3301.
   PubMed Web of Science ®Google Scholar
• Knapper S, Russell N, Gilkes A, et al. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood. 2017;129(9):1143–1154.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clinical Oncology. 2013;31(29):3681–3687.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Perl AE, Dombret H, et al. Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients ≥ 60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts). 2012;120(21):48.
   Web of Science ®Google Scholar
• Levis MJ, Perl AE, Dombret H, et al. Final results of a phase 2 open-label monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation. Blood (ASH Annual Meeting Abstracts). 2012;120(21):673.
   Google Scholar
• Cortes JE, Tallman MS, Schiller G, et al. Results of a phase 2 randomized, open-label, study of lower doses of quizartinib (AC220; ASP2689) in subjects with FLT3-ITD positive relapsed or refractory acute myeloid leukemia (AML). Blood (ASH Annual Meeting Abstracts). 2013;122(21):494.
   Web of Science ®Google Scholar
• Altman JK, Foran JM, Pratz KW, et al. Results of phase 1 study of quizartinib (AC220, ASP2689) in combination with induction and consolidation chemotherapy in younger patients with newly diagnosed acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts). 2013;122(21):623.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Bowen D, Russell N, et al. AC220 (Quizartinib) can be safely combined with conventional chemotherapy in older patients with newly diagnosed acute myeloid leukaemia: experience from the AML18 pilot trial. Blood (ASH Annual Meeting Abstracts). 2013;122:622.
   Web of Science ®Google Scholar
• Borthakur G, Kantarjian HM, O’Brien S, et al. The combination of quizartinib with azacitidine or low dose cytarabine is highly active in patients (Pts) with FLT3-ITD mutated myeloid leukemias: interim report of a phase I/II trial. Blood (ASH Annual Meeting Abstracts). 2014;124(21):388.
   Web of Science ®Google Scholar
• Cortes J, Gammon G, Khaled S, et al. Phase 3 study of quizartinib (AC220) monotherapy vs salvage chemotherapy (SC) in patients (pts) with FLT3-ITD+ acute myeloid leukemia (AML) refractory to or relapsed (R/R) after 1st-line treatment with or without hematopoietic stem cell transplant (HSCT) consolidation: the QuANTUM-R study. Ann Oncol. 2016;27(suppl_6):948TiP.
   Google Scholar
• Erba HP, Levis MJ, Sekeres MA, et al.  Phase 3 (P3) study of quizartinib (Q) or placebo (P) with induction (IND) and consolidation chemotherapy (CON) and as maintenance (MN) in patients (pts) with newly diagnosed (NDx) FLT3-ITD–positive acute myeloid leukemia (AML): the QuANTUM-first study. J Clin Oncol. 2016;34(suppl; abstr TPS7073).
   Google Scholar
• Le DL, Cao H, Yang LX. Cardiotoxicity of molecular-targeted drug therapy. Anticancer Res. 2014;34(7):3243–3249.
   PubMed Web of Science ®Google Scholar
• Yang B, Papoian T. Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome. J Appl Toxicol. 2012;32(12):945–951.
   PubMed Web of Science ®Google Scholar
• Hasinoff BB. The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity. Toxicol Appl Pharmacol. 2010;244(2):190–195.
   PubMed Web of Science ®Google Scholar
• Hasinoff BB, Patel D. The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. Toxicol Appl Pharmacol. 2010;249(2):132–139.
   PubMed Web of Science ®Google Scholar
• Randhawa JK, Kantarjian HM, Borthakur G, et al. Results of a phase ii study of Crenolanib in relapsed/refractory acute myeloid leukemia patients (Pts) with activating flt3 mutations. Blood (ASH Annual Meeting Abstracts). 2014;124:389.
   Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Kadia TM, et al. Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. J Clin Oncol. 2016;34(suppl; abstr 7008).
   Google Scholar
• Ohanian M, Kantarjian HM, Borthakur G, et al. Efficacy of a type I FLT3 inhibitor, crenolanib, with Idarubicin and high-dose Ara-C in multiply relapsed/refractory FLT3+ AML. Blood (ASH Annual Meeting Abstracts). 2016;128:2744.
   PubMed Web of Science ®Google Scholar
• Ben-Batalla I, Schultze A, Wroblewski M, et al. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood. 2013;122(14):2443–2452.
   PubMed Web of Science ®Google Scholar
• Park IK, Mishra A, Chandler J, et al. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. Blood. 2013;121(11):2064–2073.
   PubMed Web of Science ®Google Scholar
• Janning M, Ben-Batalla I, Loges S. Axl inhibition: a potential road to a novel acute myeloid leukemia therapy? Expert Rev Hematol. 2015;8(2):135–138.
   PubMed Web of Science ®Google Scholar
• Park IK, Mundy-Bosse B, Whitman SP, et al. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia. Leukemia. 2015;29(12):2382–2389.
   PubMed Web of Science ®Google Scholar
• Smith CC, Levis MJ, Litzow MR, et al. Pharmacokinetic profile and pharmacodynamic effects of ASP2215, a selective, potent inhibitor of FLT3/AXL, in patients with relapsed or refractory Acute Myeloid Leukemia: results from a first-in-human phase 1/2 study. Blood (ASH Annual Meeting Abstracts). 2015;126:4836.
   Web of Science ®Google Scholar
• Altman JK, Perl AE, Cortes JE, et al. Antileukemic activity and tolerability of ASP2215 80mg and greater in FLT3 mutation-positive subjects with relapsed or refractory Acute Myeloid Leukemia: results from a phase 1/2, open-label, dose-escalation/dose-response study. Blood (ASH Annual Meeting Abstracts). 2015;126:321.
   Web of Science ®Google Scholar
• Perl AE, Cortes JE, Strickland SA, et al.  A phase 3, open-label, randomized study of the FLT3 inhibitor gilteritinib versus salvage chemotherapy in adults with first relapse or primary refractory FLT3 mutation-positive acute myeloid leukemia. J Clin Oncol. 2016;34:suppl; abstr TPS7072.
   Google Scholar
• Daver N, Konopleva M, Kohrt HE, et al. First-in-human study of FLX925, an orally administered FLT3/CDK4/CDK6 inhibitor, in subjects with relapsed or refractory acute myeloid leukemia (AML). J Clin Oncol. 2015;33(suppl; abstr TPS7098).
   Google Scholar
• Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909–1918.
   PubMed Web of Science ®Google Scholar
• Brunet S, Labopin M, Esteve J, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clinical Oncology. 2012;30(7):735–741.
   PubMed Web of Science ®Google Scholar
• Deol A, Sengsayadeth S, Ahn KW, et al. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016;122(19):3005–3014.
   PubMed Web of Science ®Google Scholar
• DeZern AE, Sung A, Kim S, et al. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biology Blood Marrow Transplantation. 2011;17(9):1404–1409.
   PubMed Web of Science ®Google Scholar
• Chen YB, Li S, Lane AA, et al. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for FMS-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biology Blood Marrow Transplantation. 2014;20(12):2042–2048.
   PubMed Web of Science ®Google Scholar
• Brunner AM, Li S, Fathi AT, et al. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016;175(3):496–504.
   PubMed Web of Science ®Google Scholar
• Battipaglia G, Ruggeri A, Massoud R, et al. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for FMS-like tyrosine kinase 3-mutated acute myeloid leukemia. Cancer. 2017;123:2867–2874.
   PubMed Web of Science ®Google Scholar
• Sharma M, Ravandi F, Bayraktar UD, et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biology Blood Marrow Transplantation. 2011;17(12):1874–1877.
   PubMed Web of Science ®Google Scholar
• Tschan-Plessl A, Halter JP, Heim D, et al. Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation. Ann Hematol. 2015;94(11):1899–1905.
   PubMed Web of Science ®Google Scholar
• Sandmaier BM, Khaled SK, Oran B, et al. Results of a phase 1 study of Quizartinib (AC220) as maintenance therapy in subjects with Acute Myeloid Leukemia in remission following Allogeneic Hematopoietic cell transplantation. Blood (ASH Annual Meeting Abstracts). 2014;124:428a.
   Google Scholar
• Testa U, Pelosi E. The impact of flt3 mutations on the development of Acute Myeloid Leukemias. Leuk Res Treatment. 2013;2013:275760.
   PubMedGoogle Scholar
• Smith CC, Wang Q, Chin CS, et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature. 2012;485(7397):260–263.
   PubMed Web of Science ®Google Scholar
• Man CH, Fung TK, Ho C, et al. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood. 2012;119(22):5133–5143.
   PubMed Web of Science ®Google Scholar
• Ghiaur G, Levis M. Mechanisms of resistance to FLT3 Inhibitors and the role of the bone marrow microenvironment. Hematol Oncol Clin North Am. 2017;31(4):681–692.
   PubMed Web of Science ®Google Scholar
• Yang X, Sexauer A, Levis M. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase. Br J Haematol. 2014;164(1):61–72.
   PubMed Web of Science ®Google Scholar
• Kojima K, McQueen T, Chen Y, et al. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1alpha-mediated down-regulation of CXCL12. Blood. 2011;118(16):4431–4439.
   PubMed Web of Science ®Google Scholar
• Traer E, Martinez J, Javidi-Sharifi N, et al. FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in Acute Myeloid Leukemia. Cancer Res. 2016;76(22):6471–6482.
   PubMed Web of Science ®Google Scholar
• Chen F, Ishikawa Y, Akashi A, et al. Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells. Oncotarget. 2016;7(30):47018–47032.
   PubMed Web of Science ®Google Scholar
• Alonso S, Su M, Jones JW, et al. Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes. Oncotarget. 2015;6(17):14905–14912.
   PubMed Web of Science ®Google Scholar
• Moore AS, Faisal A, Gonzalez De Castro D, et al. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia. 2012;26(7):1462–1470.
   PubMed Web of Science ®Google Scholar
• Alvarado Y, Kantarjian HM, Luthra R, et al. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. Cancer. 2014;120(14):2142–2149.
   PubMed Web of Science ®Google Scholar
• Smith CC, Zhang C, Lin KC, et al. Characterizing and overriding the structural mechanism of the Quizartinib-resistant FLT3 “Gatekeeper” F691L mutation with PLX3397. Cancer Discov. 2015;5(6):668–679.
   PubMed Web of Science ®Google Scholar
• Zorn JA, Wang Q, Fujimura E, et al. Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220). PloS One. 2015;10(4):e0121177.
   PubMed Web of Science ®Google Scholar
• Zhang W, Gao C, Konopleva M, et al. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. Clinical Cancer Research. 2014;20(9):2363–2374.
   PubMed Web of Science ®Google Scholar
• Kim KT, Baird K, Ahn JY, et al. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood. 2005;105(4):1759–1767.
   PubMed Web of Science ®Google Scholar
• Kim KT, Levis M, Small D. Constitutively activated FLT3 phosphorylates BAD partially through pim-1. Br J Haematol. 2006;134(5):500–509.
   PubMed Web of Science ®Google Scholar
• Adam M, Pogacic V, Bendit M, et al. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of FMS-like tyrosine kinase 3 and BCR/ABL. Cancer Res. 2006;66(7):3828–3835.
   PubMed Web of Science ®Google Scholar
• Fathi AT, Arowojolu O, Swinnen I, et al. A potential therapeutic target for FLT3-ITD AML: PIM1 kinase. Leuk Res. 2012;36(2):224–231.
   PubMed Web of Science ®Google Scholar
• Kohl TM, Hellinger C, Ahmed F, et al. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia. 2007;21(8):1763–1772.
   PubMed Web of Science ®Google Scholar
• Bagrintseva K, Geisenhof S, Kern R, et al. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). Blood. 2005;105(9):3679–3685.
   PubMed Web of Science ®Google Scholar
• Lindblad O, Cordero E, Puissant A, et al. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML. Oncogene. 2016;35(39):5119–5131.
   PubMed Web of Science ®Google Scholar
• Piloto O, Wright M, Brown P, et al. Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood. 2007;109(4):1643–1652.
   PubMed Web of Science ®Google Scholar
• Al-Jamal HA, Mat Jusoh SA, Hassan R, et al. Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia. BMC Cancer. 2015;15:869.
   PubMed Web of Science ®Google Scholar
• Zhou J, Bi C, Janakakumara JV, et al. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood. 2009;113(17):4052–4062.
   PubMed Web of Science ®Google Scholar
• Certo M, Del Gaizo Moore V, Nishino M, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9(5):351–365.
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–208.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of Venetoclax Monotherapy in patients with acute Myelogenous Leukemia. Cancer Discov. 2016;6(10):1106–1117.
   PubMed Web of Science ®Google Scholar
• Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21(2):178–184.
   PubMed Web of Science ®Google Scholar
• Dinardo C, Pollyea D, Pratz K, et al. A phase 1b study of Venetoclax (ABT-199/GDC-0199) in combination with Decitabine or Azacitidine in treatment-naive patients with Acute Myelogenous Leukemia who are ≥ to 65 years and not eligible for standard induction therapy. Blood (ASH Annual Meeting Abstracts). 2015;126:327.
   Web of Science ®Google Scholar
• Pollyea D, Dinardo CD, Thirman MJ, et al. Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients ≥ 65 years ineligible for standard induction therapy. J Clin Oncol. 2016;34(suppl; abstr 7009).
   Google Scholar
• Lin TL, Strickland SA, Fiedler W, et al. Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age ≥ 65 with acute myelogenous leukemia. J Clin Oncol. 2016;34(suppl; abstr 7007).
   Google Scholar
• Wei A, Strickland SA, Roboz GJ, et al. Safety and efficacy of venetoclax plus low-dose Cytarabine in treatment-naive patients aged ≥65 years with Acute Myeloid Leukemia. Blood (ASH Annual Meeting Abstracts). 2016;128:102.
   Web of Science ®Google Scholar